michael baum LLC

419 lafayette street
new york, new york 10003

NYS Entity Status
ACTIVE

NYS Filing Date
JUNE 18, 2013

NYS DOS ID#
4419722

County
NEW YORK

Jurisdiction
NEW YORK

Registered Agent
NONE

NYS Entity Type
DOMESTIC LIMITED LIABILITY COMPANY

Name History
2013 - MICHAEL BAUM LLC









Buffer



submit to reddit

Telephone
n/a

Fax
n/a

Website
n/a

Email address
n/a

LinkedIn
n/a

Facebook
n/a

Google+
n/a

Twitter
n/a

Pinterest
n/a

Instagram
n/a



  • Around the Web

  • The Top 10 Moments of New York Fashion Week
    By THE NEW YORK TIMES - Friday Sep 15, 2017

    Highlights from the shows, including a celebrity-packed front row at Calvin Klein and a trek to Bedford Hills, N.Y., to see Ralph Lauren’s vintage cars.

    Source: NYT > Home Page
  • Women of Sex Tech, Unite
    By ANNA NORTH - Friday Aug 18, 2017

    New York is becoming a cultural center for young women trying to disrupt the male-dominated industries of design engineering and sex toys.

    Source: NYT > Home Page
  • Fit City: Taking Night-Life Cue, Gyms Lower the Lights
    By TATIANA BONCOMPAGNI - Tuesday Jun 13, 2017

    Cycling, boxing and running studios, as well as some full-service gyms, are using sophisticated lighting systems to heighten the exercise experience.

    Source: NYT > Home Page
  • What Steps Should NY Biotech Take in 2018? Share Your View on Dec. 11
    By Ben Fidler - Monday Nov 20, 2017

    Change takes time. Particularly in the life sciences, where a single drug’s journey from idea to market can consist of more than a decade of small, yet critical steps. For New York, then, aspirations to become a region known for its biotech industry are—and always have been—a long game in which every year and bit […]

    Source: Xconomy New York
  • Acorda Scraps One Parkinson’s Drug, Puts Its Cash Behind Another
    By Frank Vinluan - Monday Nov 20, 2017

    Acorda Therapeutics said Monday that it will stop work on an experimental treatment for Parkinson’s disease, spelling the end for a drug the Ardsley, NY, company added to its pipeline last year in a $363 million deal. The announcement follows the recent emergence of safety problems for the Acorda (NASDAQ: ACOR) drug, tozadenant. Acorda said […]

    Source: Xconomy New York